<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Newborn screening for critical congenital heart disease using pulse oximetry</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Newborn screening for critical congenital heart disease using pulse oximetry</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Newborn screening for critical congenital heart disease using pulse oximetry</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matt Oster, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David R Fulton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1212691257"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital heart disease (CHD) is the most common congenital disorder in newborns [<a href="#rid1">1-3</a>]. Critical CHD, defined as requiring surgery or catheter-based intervention in the first year of life (<a class="graphic graphic_table graphicRef103087" href="/z/d/graphic/103087.html" rel="external">table 1</a>), accounts for approximately 25 percent of all CHD [<a href="#rid4">4</a>]. Although many newborns with critical CHD are symptomatic and identified soon after birth, others are not diagnosed until after discharge from the birth hospitalization [<a href="#rid5">5-8</a>]. In infants with critical cardiac lesions, the risk of morbidity and mortality increases when there is a delay in diagnosis and timely referral to a tertiary center with expertise in treating these patients [<a href="#rid9">9-11</a>].</p><p>Newborn pulse oximetry screening (POS) for detection of critical CHD will be reviewed here. The presentation of critical CHD and management of specific cardiac conditions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/5780.html" rel="external">"Cardiac causes of cyanosis in the newborn"</a> and  <a class="medical medical_review" href="/z/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn"</a>.)</p><p class="headingAnchor" id="H178679878"><span class="h1">DEFINITION AND TARGETED LESIONS</span><span class="headingEndMark"> — </span>The following terms are used in this topic:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Critical CHD</strong> – Critical CHD refers to lesions requiring surgery or catheter-based intervention in the first year of life. This category includes ductal-dependent and cyanotic lesions as well as less severe forms of CHD that are not dependent on the patent ductus arteriosus (PDA) (<a class="graphic graphic_table graphicRef103087" href="/z/d/graphic/103087.html" rel="external">table 1</a>). Critical CHD accounts for approximately 25 percent of all CHD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted lesions</strong> – CHD lesions targeted by pulse oximetry screening (POS) include defects that typically: (A) require intervention in the first year of life, and (B) present with hypoxemia some or most of the time [<a href="#rid12">12-14</a>]. These include but are not limited to the following defects. While POS improves early identification of infants with these defects, some affected newborns (particularly those with coarctation of the aorta) may pass the POS. (See <a class="local">'Negative screen'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypoplastic left heart syndrome (<a class="graphic graphic_figure graphicRef82280" href="/z/d/graphic/82280.html" rel="external">figure 1</a>) (see  <a class="medical medical_review" href="/z/d/html/14370.html" rel="external">"Hypoplastic left heart syndrome: Anatomy, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary atresia with intact ventricular septum (<a class="graphic graphic_figure graphicRef101334" href="/z/d/graphic/101334.html" rel="external">figure 2</a>) (see  <a class="medical medical_review" href="/z/d/html/87462.html" rel="external">"Pulmonary atresia with intact ventricular septum (PA/IVS)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary atresia with ventricular septal defect </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tetralogy of Fallot (<a class="graphic graphic_figure graphicRef82493" href="/z/d/graphic/82493.html" rel="external">figure 3</a>) (see  <a class="medical medical_review" href="/z/d/html/5769.html" rel="external">"Tetralogy of Fallot (TOF): Pathophysiology, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total anomalous pulmonary venous connection (<a class="graphic graphic_figure graphicRef77375" href="/z/d/graphic/77375.html" rel="external">figure 4</a>) (see  <a class="medical medical_review" href="/z/d/html/5767.html" rel="external">"Total anomalous pulmonary venous connection"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transposition of the great arteries (<a class="graphic graphic_figure graphicRef68589" href="/z/d/graphic/68589.html" rel="external">figure 5</a>) (see  <a class="medical medical_review" href="/z/d/html/14374.html" rel="external">"D-transposition of the great arteries (D-TGA): Anatomy, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tricuspid atresia (<a class="graphic graphic_figure graphicRef88605" href="/z/d/graphic/88605.html" rel="external">figure 6</a>) (see  <a class="medical medical_review" href="/z/d/html/14587.html" rel="external">"Tricuspid valve atresia"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Truncus arteriosus (<a class="graphic graphic_figure graphicRef83846" href="/z/d/graphic/83846.html" rel="external">figure 7</a>) (see  <a class="medical medical_review" href="/z/d/html/14588.html" rel="external">"Truncus arteriosus"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coarctation of the aorta (<a class="graphic graphic_figure graphicRef103747" href="/z/d/graphic/103747.html" rel="external">figure 8</a>) (see  <a class="medical medical_review" href="/z/d/html/5760.html" rel="external">"Clinical manifestations and diagnosis of coarctation of the aorta"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Interrupted aortic arch (<a class="graphic graphic_figure graphicRef103748" href="/z/d/graphic/103748.html" rel="external">figure 9</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Critical aortic stenosis (see  <a class="medical medical_review" href="/z/d/html/5775.html" rel="external">"Valvar aortic stenosis in children", section on 'Critical aortic stenosis'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Critical pulmonic stenosis (see  <a class="medical medical_review" href="/z/d/html/14578.html" rel="external">"Pulmonic stenosis in infants and children: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Double-outlet right ventricle</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ebstein anomaly (<a class="graphic graphic_figure graphicRef79822" href="/z/d/graphic/79822.html" rel="external">figure 10</a>) (see  <a class="medical medical_review" href="/z/d/html/8146.html" rel="external">"Ebstein anomaly: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other single ventricle defects</p><p></p><p class="headingAnchor" id="H1212692118"><span class="h1">PREVALENCE OF CRITICAL CONGENITAL HEART DISEASE</span><span class="headingEndMark"> — </span>CHD is the most common congenital disorder in newborns, with a birth prevalence of approximately 1 to 2 percent [<a href="#rid1">1-3</a>]. Up to 25 percent of infants with CHD have a "critical" defect. Numerous familial, maternal, and pregnancy-related factors have been reported to be associated with an increased risk of CHD (<a class="graphic graphic_table graphicRef103088" href="/z/d/graphic/103088.html" rel="external">table 2</a>). In addition, CHD is a common finding in a number of genetic syndromes (<a class="graphic graphic_table graphicRef81423" href="/z/d/graphic/81423.html" rel="external">table 3</a>). The epidemiology of critical CHD is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Epidemiology'</a>.)</p><p>In a population-based study from Sweden, a total of 630 infants were diagnosed with critical CHD from 2014 through 2019, yielding an estimated prevalence of 0.9 per 1000 live births [<a href="#rid15">15</a>]. In 42 percent of cases, the diagnosis was made prenatally; in 25 percent of cases, the diagnosis came to light due to physical examination and/or clinical symptoms in the newborn; and in 23 percent of cases, the diagnosis came to light based upon POS (which has been standard practice in Sweden since 2013). The remaining 10 percent of infants were diagnosed after discharge from the birth hospitalization. In addition, there were four patients (0.6 percent) who died during the birth hospitalization without being diagnosed with critical CHD (ie, the defect was identified on autopsy). </p><p class="headingAnchor" id="H8721498"><span class="h1">CONSEQUENCES OF LATE DETECTION</span><span class="headingEndMark"> — </span>Most newborns with critical CHD are diagnosed either prenatally or upon clinical examination during the birth hospitalization. However, up to 30 percent of newborns with critical CHD appear healthy on routine examination, and signs of critical CHD may not be apparent in the first days of life [<a href="#rid16">16,17</a>]. Cyanosis may not be clinically apparent in patients with mild desaturation (&gt;80 percent saturation) or anemia [<a href="#rid18">18</a>]. In newborns with dark skin pigmentation, cyanosis can be especially difficult to appreciate. (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Postnatal diagnosis'</a>.)</p><p>The timing of presentation varies with the underlying lesion and its dependence upon a patent ductus arteriosus (PDA). In patients with ductal-dependent lesions (<a class="graphic graphic_table graphicRef103087" href="/z/d/graphic/103087.html" rel="external">table 1</a>), closure of the PDA within the first few days of life can precipitate rapid clinical deterioration with potentially life-threatening consequences (ie, severe metabolic acidosis, seizures, cardiogenic shock, cardiac arrest, or end-organ injury) [<a href="#rid19">19</a>]. Other patients may have lesions that are not dependent on the patency of the PDA (eg, total anomalous pulmonary venous return, truncus arteriosus), yet delayed diagnosis can similarly lead to poor outcomes. For infants with critical CHD who are not diagnosed during the birth hospitalization, the risk of mortality is as high as 30 percent [<a href="#rid9">9,11,20</a>].</p><p>In a population-based observational study of 3603 infants with critical CHD born in 1998 to 2007 (prior to institution of routine newborn pulse oximetry screening [POS]) identified through a state Birth Defects Registry, approximately one-quarter of patients were not diagnosed during the birth hospitalization [<a href="#rid21">21</a>]. In this group of late-detected critical CHD (n = 825), there were 15 deaths (2 percent) which were deemed to be potentially preventable. In addition, adjusted multivariable analysis showed that infants with late-detected critical CHD had a greater number of admissions, more hospitalized days, and higher inpatient costs than those diagnosed prenatally or during the birth hospitalization.</p><p>In a simulation model based upon estimates of birth prevalence, prenatal diagnosis rates, late detection rates, and sensitivity of POS, one study estimated that 875 infants with critical CHD will be detected annually in the United States through newborn screening [<a href="#rid17">17</a>]. An additional 880 false-negative screenings are expected.</p><p class="headingAnchor" id="H1407702646"><span class="h1">BENEFITS OF SCREENING</span></p><p class="headingAnchor" id="H127903176"><span class="h2">Early detection of critical CHD</span><span class="headingEndMark"> — </span>The primary benefit of newborn pulse oximetry screening (POS) for critical CHD is timely identification of newborns with critical CHD prior to discharge from the birth hospitalization, thereby minimizing the morbidity and mortality associated with delayed diagnosis.</p><p>Universal newborn POS improves detection of critical CHD compared with physical examination alone [<a href="#rid10">10,15,22</a>]. In one large prospective study, there was a lower rate of missed diagnoses of critical CHD for newborns born in the region that routinely performed POS compared with those born in regions where newborns were not routinely screened (8 versus 28 percent) [<a href="#rid10">10</a>]. In addition, no infant died from a ductal-dependent lesion in the region utilizing routine POS versus five deaths in regions without routine screening.</p><p>In a report of one statewide screening program (2011 to 2012) that successfully screened 99 percent of 73,320 eligible newborns born during the study period, 49 newborns had a positive screen and underwent further diagnostic evaluation [<a href="#rid23">23</a>]. Of the 49 newborns with positive screens, 19 had additional signs and symptoms that would have triggered a diagnostic evaluation, whereas 30 underwent evaluation based solely upon the screening result. Of these, three had previously undiagnosed critical CHD.</p><p>Further evidence supporting newborn POS comes from studies demonstrating reductions in unplanned CHD hospitalizations and CHD-related mortality among infants born in regions where screening policies have been implemented [<a href="#rid24">24,25</a>]. In one study, implementation of mandatory statewide newborn POS programs was associated with a 33 percent reduction in early infant CHD-related mortality compared with states without mandatory screening (absolute decrease of 4 deaths per 100,000 births) [<a href="#rid24">24</a>]. In another study, CHD-related emergency hospitalizations during the first three months after birth were lower in states that had implemented mandatory newborn POS compared with the pre-implementation era and states without mandatory screening (absolute difference of 5.5 fewer hospitalizations per 10,000 live births; adjusted rate ratio [aRR] 0.78, 95% CI 0.64-0.94) [<a href="#rid25">25</a>]. In this study, the impact of POS on reducing hospitalizations differed according to race, with less of an impact among Black infants. This finding highlights the importance of considering healthcare disparities and equity when implementing screening programs.</p><p class="headingAnchor" id="H3277280570"><span class="h2">Detection of other serious conditions</span><span class="headingEndMark"> — </span>A secondary benefit of newborn POS is that it identifies other serious neonatal conditions associated with hypoxemia. Common noncardiac causes of hypoxemia that are identified through newborn POS include [<a href="#rid14">14,23,26-28</a>] (see  <a class="medical medical_review" href="/z/d/html/14305.html" rel="external">"Approach to cyanosis in the newborn", section on 'Causes of central cyanosis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia (see  <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">"Neonatal pneumonia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Transient tachypnea of the newborn (TTN) (see  <a class="medical medical_review" href="/z/d/html/5066.html" rel="external">"Transient tachypnea of the newborn"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory distress syndrome (RDS) (see  <a class="medical medical_review" href="/z/d/html/5055.html" rel="external">"Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent pulmonary hypertension of the newborn (PPHN) (see  <a class="medical medical_review" href="/z/d/html/5045.html" rel="external">"Persistent pulmonary hypertension of the newborn (PPHN): Clinical features and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Meconium aspiration syndrome (MAS) (see  <a class="medical medical_review" href="/z/d/html/4971.html" rel="external">"Meconium aspiration syndrome: Pathophysiology, clinical manifestations, and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumothorax (see  <a class="medical medical_review" href="/z/d/html/4995.html" rel="external">"Pulmonary air leak in the newborn"</a>)</p><p></p><p>Many newborns who screen positive are ultimately found to have one of these conditions. In a study of 253 newborns who had positive screening results, only 22 (9 percent) were ultimately found to have clinically significant CHD [<a href="#rid28">28</a>]. Of the 231 newborns without CHD, 97 percent were diagnosed with serious noncardiac conditions, including pneumonia (33 percent), TTN (26 percent), sepsis (23 percent), PPHN (8 percent), MAS (4 percent), pneumothorax (1 percent), and RDS (1 percent). In the remaining six newborns, the abnormal POS result was attributed to transitional circulation. (See  <a class="medical medical_review" href="/z/d/html/4964.html" rel="external">"Overview of neonatal respiratory distress and disorders of transition", section on 'Transition from fetal life'</a>.)</p><p class="headingAnchor" id="H1407702652"><span class="h1">HARMS OF SCREENING</span><span class="headingEndMark"> — </span>The potential benefits of screening must be weighed against the downside of false positives. In a 2018 meta-analysis of 21 studies including &gt;450,000 newborns, the pooled false-positive rate was 0.14 percent (95% CI 0.7-0.22) [<a href="#rid29">29</a>]. Newborns with false-positive screening results undergo additional testing and/or transfer to centers with more advanced pediatric cardiac care. This additional testing has the potential to cause discomfort or harm to the newborn and cause anxiety in the parents. It is important to recognize, however, that in many cases, the evaluation results in identification of other causes of hypoxemia. (See <a class="local">'Detection of other serious conditions'</a> above.)</p><p>In a study evaluating the acceptability of POS to the parents of newborns, parents were mostly satisfied with screening, perceived it as an important test, and would recommend it to others [<a href="#rid30">30</a>]. Mothers given false-positive results were not found to be more anxious after screening than those given true negative results, although they were less satisfied with the test.</p><p class="headingAnchor" id="H1212693472"><span class="h1">APPROACH TO SCREENING</span></p><p class="headingAnchor" id="H384309564"><span class="h2">Screening algorithms</span><span class="headingEndMark"> — </span>In the United States, the 2011 AAP-endorsed guideline is the most commonly used algorithm for newborn POS (<a class="graphic graphic_algorithm graphicRef103086" href="/z/d/graphic/103086.html" rel="external">algorithm 1A</a>) [<a href="#rid31">31-33</a>]. Alternative algorithms include the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.nj.gov%2Fhealth%2Ffhs%2Fnbs%2Fdocuments%2Falgorithm.pdf&amp;token=MSjVRYqxbJaCTRbu9giOufxIU5FqlGiTtvXNT8UD0Ftkp%2BXC73o35QS8cgugDTNGhj6%2FroU5qQVp7zJ9hopdBA%3D%3D&amp;TOPIC_ID=101291" target="_blank">New Jersey</a> algorithm [<a href="#rid23">23</a>], the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tn.gov%2Fcontent%2Fdam%2Ftn%2Fhealth%2Fdocuments%2FCCHD_Screening_Protocol_Algorithm.pdf&amp;token=aTo0RMf1PxGKcS34hAnXxD9QSS4JZiarUA4KfFrMg9rcDsTuUpqbus%2FITlSj6hpojcC%2F9B4UU4yazu8MllUvSfxVqhg21oGai73ARroPZkOX1%2BvfXr%2Fz3V16MJIuzkLK&amp;TOPIC_ID=101291" target="_blank">Tennessee</a> algorithm [<a href="#rid34">34</a>], and other modifications to the 2011 AAP algorithm [<a href="#rid35">35</a>]. </p><p>In 2018, an expert panel was convened to review screening practices in the United States and to identify opportunities to improve screening process [<a href="#rid33">33</a>]. From this meeting, a new algorithm was proposed (<a class="graphic graphic_algorithm graphicRef139676" href="/z/d/graphic/139676.html" rel="external">algorithm 1B</a>). This modified algorithm has been adopted by many states. </p><p class="headingAnchor" id="H1908478466"><span class="h2">Timing</span><span class="headingEndMark"> — </span>Screening should be performed after 24 hours of life or as late as possible if early discharge is planned. Screening within the first 24 hours of life is not as specific as later screening, because hypoxemia commonly occurs during the transition from intrauterine to extrauterine life conditions [<a href="#rid36">36-39</a>]. (See  <a class="medical medical_review" href="/z/d/html/4964.html" rel="external">"Overview of neonatal respiratory distress and disorders of transition"</a>.)</p><p class="headingAnchor" id="H1908478472"><span class="h2">Technique</span><span class="headingEndMark"> — </span>Screening should be performed by qualified and trained personnel [<a href="#rid40">40</a>]. Oxygen saturation (SpO<sub>2</sub>) is measured in the right hand (preductal) <strong>and</strong> either foot (postductal) (<a class="graphic graphic_algorithm graphicRef103086" href="/z/d/graphic/103086.html" rel="external">algorithm 1A</a>). Screening at both locations can occur simultaneously or in direct sequence. Postductal measurement of SpO<sub>2</sub> is important because defects with right-to-left shunting of desaturated blood through the ductus arteriosus will not be detected with only preductal measurement.</p><p>The screening should be performed using a motion-tolerant pulse oximeter. Either disposable or reusable probes can be used. Reusable probes reduce the cost of screening but must be appropriately cleaned to minimize the risk of infection. Measurements should not be performed when the newborn is crying or moving, because this reduces the quality of the signal and the accuracy of the test [<a href="#rid36">36,41</a>]. In addition, pulse oximetry testing may fail to detect hypoxemia if there is interference from ambient light, partial probe detachment, electromagnetic interference, poor perfusion at the site of measurement, and/or hemoglobinopathy [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/1612.html" rel="external">"Pulse oximetry"</a>.)</p><p class="headingAnchor" id="H1212693478"><span class="h1">POSITIVE SCREEN</span></p><p class="headingAnchor" id="H1908479986"><span class="h2">Criteria for positive screen</span><span class="headingEndMark"> — </span>Criteria for a positive screen (ie, "failing" the screen) using the 2011 American Academy of Pediatrics (AAP)-endorsed algorithm (<a class="graphic graphic_algorithm graphicRef103086" href="/z/d/graphic/103086.html" rel="external">algorithm 1A</a>) and the modified 2018 algorithm (<a class="graphic graphic_algorithm graphicRef139676" href="/z/d/graphic/139676.html" rel="external">algorithm 1B</a>) are generally similar. The main difference between the two algorithms is that for newborns who neither pass nor fail on the initial screen, the modified algorithm requires only one repeat screen; whereas the original 2011 algorithm required two repeat screens. </p><p>A positive screen is indicated by <strong>any</strong> of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen saturation (SpO<sub>2</sub>) measurement &lt;90 percent in either extremity</p><p class="bulletIndent1"><span class="glyph">●</span>SpO<sub>2</sub> measurement 90 to 94 percent in both the right hand and a lower extremity on two to three measurements, each separated by one hour</p><p class="bulletIndent1"><span class="glyph">●</span>SpO<sub>2</sub> difference ≥4 percent between the upper and lower extremities on two to three measurements, each separated by one hour</p><p></p><p>A cutoff SpO<sub>2</sub> value of &lt;95 percent is used as it provides a sensitivity of around 75 percent and specificity &gt;99 percent [<a href="#rid26">26,29,43</a>]. In a 2018 meta-analysis of 21 studies including &gt;450,000 newborns who were screened using a cutoff SpO<sub>2</sub> threshold of &lt;95 or ≤95 percent, the sensitivity for detection of critical CHD was 76.3 percent (95% CI 69.5-82) and specificity was 99.9 percent (95% CI 99.7-99.9) [<a href="#rid29">29</a>].</p><p>The characteristics of the screening test will depend on which algorithm is being used [<a href="#rid44">44</a>]. The New Jersey algorithm, which considers SpO<sub>2</sub> &lt;95 percent in either extremity on three measurements to be a positive screen, has a higher sensitivity but lower specificity than the 2011 AAP algorithm. The Tennessee algorithm, which initially tests only the lower extremity and considers an initial SpO<sub>2</sub> of at least 97 percent to be a negative screen, has lower resource utilization than the AAP algorithm but may have lower sensitivity. The 2018 modified algorithm is expected to perform similar to the New Jersey algorithm, with potentially a slightly higher false-positive rate.</p><p>As the SpO<sub>2</sub> threshold is decreased, the sensitivity of pulse oximetry to detect critical CHD decreases and the specificity increases [<a href="#rid36">36,45</a>]. In a study that evaluated different criteria for an abnormal pulse oximetry test, lowering the SpO<sub>2</sub> threshold from &lt;95 to &lt;90 percent resulted in greater specificity (88 versus 100 percent, respectively) but lower sensitivity (75 versus 53 percent, respectively) [<a href="#rid45">45</a>]. Hence, using a lower SpO<sub>2</sub> threshold decreases the number of false positives and thus may avoid unnecessary transfers, echocardiograms, and pediatric cardiology consultations. However, this comes at the cost of potentially missing some newborns with critical CHD.</p><p>In a multicenter prospective study of 122,738 newborn newborns born between 2011 and 2012, the sensitivity of detecting critical CHD was greatest using the combination of pulse oximetry plus clinical assessment (93 percent) compared with either pulse oximetry alone (84 percent) or clinical assessment alone (77 percent) [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H1908478726"><span class="h2">Assessment of newborns with positive screens</span><span class="headingEndMark"> — </span>A neonate with hypoxemia should be not discharged from the hospital without excluding potentially life-threatening conditions. Newborns with positive screening results should undergo evaluation to identify the cause of hypoxemia. (See  <a class="medical medical_review" href="/z/d/html/14305.html" rel="external">"Approach to cyanosis in the newborn", section on 'Evaluation'</a>.)</p><p>If a noncardiac cause of the hypoxemia cannot be identified, then evaluation of critical CHD as the cause should include high-quality echocardiography, with interpretation by a clinician with expertise in the diagnosis of CHD. Patients should have access to these diagnostic services at the birth center, via telemedicine, or via short-distance transport. Each birthing institution should establish a protocol to ensure a timely evaluation for newborns with a positive screening test. However, evaluation of the baby with low SpO<sub>2</sub> using other means (eg, chest radiograph, blood work) should not be delayed while awaiting an echocardiogram. (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Diagnostic approach'</a>.)</p><p>Common noncardiac causes of hypoxemia that are identified through newborn POS include [<a href="#rid14">14,23,26-28</a>] (see  <a class="medical medical_review" href="/z/d/html/14305.html" rel="external">"Approach to cyanosis in the newborn", section on 'Causes of central cyanosis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia (see  <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">"Neonatal pneumonia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Transient tachypnea of the newborn (TTN) (see  <a class="medical medical_review" href="/z/d/html/5066.html" rel="external">"Transient tachypnea of the newborn"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory distress syndrome (RDS) (see  <a class="medical medical_review" href="/z/d/html/5055.html" rel="external">"Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent pulmonary hypertension of the newborn (PPHN) (see  <a class="medical medical_review" href="/z/d/html/5045.html" rel="external">"Persistent pulmonary hypertension of the newborn (PPHN): Clinical features and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Meconium aspiration syndrome (MAS) (see  <a class="medical medical_review" href="/z/d/html/4971.html" rel="external">"Meconium aspiration syndrome: Pathophysiology, clinical manifestations, and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumothorax (see  <a class="medical medical_review" href="/z/d/html/4995.html" rel="external">"Pulmonary air leak in the newborn"</a>)</p><p></p><p>In newborns in whom an alternative cause (other than critical CHD) is identified and treated, an echocardiogram may not be needed if the hypoxemia resolves. (See  <a class="medical medical_review" href="/z/d/html/4964.html" rel="external">"Overview of neonatal respiratory distress and disorders of transition"</a>.)</p><p>If critical CHD is identified on echocardiography, urgent consultation with a pediatric cardiologist and/or transfer to a medical facility with pediatric cardiology expertise is warranted. Newborns with ductal-dependent lesions are at increased risk for death and significant morbidity unless interventions are initiated to maintain patency of the ductus arteriosus, ensure adequate mixing of deoxygenated and oxygenated blood, and/or relieve obstructed blood flow. (See  <a class="medical medical_review" href="/z/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'Initial management'</a>.)</p><p class="headingAnchor" id="H446271559"><span class="h1">NEGATIVE SCREEN</span><span class="headingEndMark"> — </span>Newborns with negative screening results (ie, those who "pass" the test) who are clinically well without signs concerning possible CHD (eg, cardiac murmur, weak femoral pulses) do not require additional evaluation. However, it is important to recognize that infants with a negative screen may still have critical CHD because hypoxemia may not be present all of the time in some CHD lesions. </p><p>It is estimated that universal newborn POS may miss as many cases of critical CHD as it detects [<a href="#rid15">15,17</a>]. POS cannot "rule out" the presence of critical CHD [<a href="#rid46">46</a>]. In addition, POS will not detect noncritical CHD lesions that are nonetheless clinically significant (eg, aortic stenosis, large atrial or ventricular defects) [<a href="#rid27">27</a>]. If there is clinical suspicion for CHD, additional evaluation should be pursued even in the setting of a normal pulse oximetry result. (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/5765.html" rel="external">"Suspected heart disease in infants and children: Criteria for referral"</a>.)</p><p>In a population-based study from Sweden that included 292 infants with critical CHD who had POS performed during the birth hospitalization, 51 percent had a negative screening result [<a href="#rid15">15</a>]. Coarctation of the aorta (CoA), severe pulmonic stenosis (PS), and severe aortic stenosis (AS) were the diagnoses that POS most frequently failed to detect. POS was negative in 83 percent of patients with CoA, 75 percent of patients with severe AS, and 35 percent of patients with severe PS.</p><p class="headingAnchor" id="H446271576"><span class="h1">SPECIAL SETTINGS</span></p><p class="headingAnchor" id="H1908478974"><span class="h2">High altitude</span><span class="headingEndMark"> — </span>False-positive rates are higher in centers at high altitude [<a href="#rid47">47,48</a>]. The pulse oximetry screening (POS) guidelines recommended by the American Academy of Pediatrics (AAP) are feasible up to an elevation of 2643 feet (806 meters) without any needed adjustments [<a href="#rid49">49,50</a>]. Criteria have not been validated for newborns cared for at centers at higher altitudes [<a href="#rid51">51</a>]. A modified protocol has been proposed for testing at moderate altitude [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H446271861"><span class="h2">Out-of-hospital delivery</span><span class="headingEndMark"> — </span>For newborns delivered out-of-hospital (ie, home births and birth centers), critical CHD screening using pulse oximetry can be performed using portable pulse oximetry probes [<a href="#rid53">53-58</a>]. Care providers in these situations should have protocols in place to manage the newborn who fails screening in accordance with published guidelines. (See  <a class="medical medical_review" href="/z/d/html/4456.html" rel="external">"Birth centers"</a> and  <a class="medical medical_review" href="/z/d/html/4454.html" rel="external">"Planned home birth", section on 'Special issues'</a>.)</p><p class="headingAnchor" id="H446271868"><span class="h2">Neonatal intensive care unit</span><span class="headingEndMark"> — </span>There are no clear guidelines for performing screening in the neonatal intensive care unit (NICU) setting, yet these newborns are similarly at risk for undetected critical CHD. Most neonates admitted to NICUs have pulse oximetry performed as part of their routine care; however, protocols used in newborn nurseries to identify critical CHD may not be appropriate for the NICU [<a href="#rid59">59,60</a>]. A modified protocol has been proposed for use in the NICU [<a href="#rid61">61</a>].</p><p>Premature infants may have a higher false-positive rate due to having lower saturations at baseline as compared with term newborns. False negatives may also occur in this population because pulse oximetry may overestimate the arterial oxygen saturation (SpO<sub>2</sub>; as compared with direct measurement via co-oximetry) [<a href="#rid60">60</a>]. In addition, POS may be delayed because many neonates in the NICU setting require supplemental oxygen during the initial days of life [<a href="#rid62">62</a>]. Unless mandated by state law, the child who has had a postnatal echocardiogram may not separately need pulse oximetry testing to be performed. Further work in this area is needed.</p><p class="headingAnchor" id="H1212691025"><span class="h1">COST-EFFECTIVENESS</span><span class="headingEndMark"> — </span>The cost of a universal critical CHD screening program includes the direct costs of pulse oximetry (equipment, training of personnel, staff time required for screening) and the costs of further evaluation and possible transfer of patients who fail the initial screening oximetry test [<a href="#rid32">32</a>]. The cost and quality of follow-up vary depending on the accessibility and cost of pediatric cardiac subspecialty care and the need for transfer. In the United States, the additional cost for pulse oximetry universal screening has been estimated to be around $5 to $6 per newborn [<a href="#rid63">63,64</a>].</p><p>Critical CHD screening may result in reducing the costs associated with delayed diagnosis of critical CHD. As mentioned above, in a population-based observational study of 3603 infants with critical CHD, there was a greater number of admissions, more hospitalized days, and higher inpatient costs among infants with late-detected CHD (n = 825) compared with those who were diagnosed prenatally or during the birth hospitalization. The authors suggest that screening may lead to decreased costs, but further prospective studies are needed to confirm this.</p><p>In studies of the cost-effectiveness of newborn POS, the incremental cost of pulse oximetry plus clinical examination compared with examination alone have been estimated to be $20,000 to $35,000 per timely diagnosis [<a href="#rid64">64,65</a>]. The cost per life-year gained is estimated to be approximately $12,000 to $40,000 [<a href="#rid64">64,66</a>]. The greatest variation in costs between centers is in the use of equipment, with the use of reusable probes leading to considerable cost savings as compared with disposable probes [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H1212691137"><span class="h1">IMPLEMENTATION</span><span class="headingEndMark"> — </span>Universal newborn screening for critical CHD is endorsed by the American Academy of Pediatrics (AAP), American Heart Association (AHA), and American College of Cardiology (ACC) [<a href="#rid31">31,32</a>]. Screening was added to the United States Recommended Uniform Screening Panel in 2011. Since then, all 50 states and the District of Columbia have implemented policies mandating that critical CHD screening be performed or offered [<a href="#rid68">68</a>]. However, not all states have data systems in place for tracking screening results and outcomes. Screening programs are also in place in some European countries and other parts of the world [<a href="#rid69">69-72</a>]. </p><p>In 2012, an expert panel developed the following consensus recommendations for implementation of newborn POS [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Selection of screening equipment, which should be approved for hospital use in neonates by the US Food and Drug Administration (FDA), should also be tolerant of motion, use a neonatal sensor, and not require a fixation method. Of note, the FDA has not tested the performance of oximeters in critical CHD screening protocols.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Establishment of reporting standards for each birth facility and state public health monitoring. This includes patient demographic information, results of oximetry screening, type of protocol and oximeter used, and the requirements for reporting by birth facilities to public health programs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Training of health care providers and education of families. Development of educational material for both staff and families.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing assessment of the outcome of screening, particularly in the context of other screening efforts (eg, fetal ultrasound), noncardiac conditions, quality of the equipment, cost of screening including educational efforts, and reimbursement.</p><p></p><p>Implementation of critical CHD screening varies by state and county. Clinicians should refer to the guidelines of their local public health agency to determine the appropriate algorithm and protocols for their practice area.</p><p class="headingAnchor" id="H1410041252"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115414.html" rel="external">"Society guideline links: Congenital heart disease in infants and children"</a>.)</p><p class="headingAnchor" id="H1212694604"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance</strong> – Congenital heart disease (CHD) is the most common congenital disorder in newborns. Critical CHD, defined as requiring surgery or catheter-based intervention in the first year of life (<a class="graphic graphic_table graphicRef103087" href="/z/d/graphic/103087.html" rel="external">table 1</a>), accounts for approximately 25 percent of all CHD. In infants with critical cardiac lesions, the risk of morbidity and mortality increases when there is a delay in diagnosis and timely referral to a tertiary center with expertise in treating these patients. (See <a class="local">'Prevalence of critical congenital heart disease'</a> above and <a class="local">'Consequences of late detection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for screening</strong> – The goal of critical CHD screening in newborns is to reduce mortality and morbidity associated with delayed diagnosis by identifying newborns with critical CHD in a timely manner. There is evidence that universal newborn pulse oximetry screening (POS) improves the identification of patients with critical CHD compared with physical examination alone and may lead to decreased infant morbidity and mortality from critical CHD. (See <a class="local">'Benefits of screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted lesions</strong> – CHD lesions targeted by POS include defects that typically (A) require intervention in the first year of life, and (B) present with hypoxemia some or most of the time. (See <a class="local">'Definition and targeted lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to screening</strong> – For all newborns, we suggest routine POS to detect critical CHD (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Approach to screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening is performed at &gt;24 hours after birth or as late as possible if early discharge is planned. Oxygen saturation (SpO<sub>2</sub>) should be measured in the right hand (preductal)<strong> and</strong> either foot (postductal) (<a class="graphic graphic_algorithm graphicRef103086 graphicRef139676" href="/z/d/graphic/103086.html" rel="external">algorithm 1A-B</a>). (See <a class="local">'Timing'</a> above and <a class="local">'Technique'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Criteria for a positive screen using the 2011 algorithm (<a class="graphic graphic_algorithm graphicRef103086" href="/z/d/graphic/103086.html" rel="external">algorithm 1A</a>) and the modified 2018 algorithm (<a class="graphic graphic_algorithm graphicRef139676" href="/z/d/graphic/139676.html" rel="external">algorithm 1B</a>) are generally similar. The main difference between the two algorithms is that for newborns who neither pass nor fail on the initial screen, the modified algorithm requires only one repeat screen, whereas the original 2011 algorithm required two repeat screens. A positive screen is indicated by <strong>any</strong> of the following (see <a class="local">'Criteria for positive screen'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>SpO<sub>2</sub> &lt;90 percent in either extremity</p><p class="bulletIndent3"><span class="glyph">-</span>SpO<sub>2</sub> 90 to 94 percent in both the right hand and a lower extremity on two to three measurements, each separated by one hour</p><p class="bulletIndent3"><span class="glyph">-</span>SpO<sub>2</sub> difference ≥4 percent between the upper and lower extremities on two to three measurements, each separated by one hour</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The screening procedure may require modification in certain settings, such as high altitude, out-of-hospital births (ie, home births and birth centers), and infants admitted to neonatal intensive care units (NICUs). (See <a class="local">'Special settings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of newborns with positive screening results</strong> – Newborns with positive screening results should undergo evaluation to identify the cause of hypoxemia. If critical CHD is identified on echocardiography, urgent consultation with a pediatric cardiologist and/or transfer to a medical facility with pediatric cardiology expertise is warranted. (See <a class="local">'Assessment of newborns with positive screens'</a> above and  <a class="medical medical_review" href="/z/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'Initial management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative screen</strong> – Newborns with a negative screen may still have critical CHD because hypoxemia may not be present all of the time in some CHD lesions, particularly coarctation of the aorta. If there is clinical suspicion for critical CHD, additional evaluation should be pursued even in the setting of a normal pulse oximetry result. (See <a class="local">'Negative screen'</a> above and  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Implementation</strong> – In the United States, all states require that newborn POS for critical CHD be offered. Screening programs are also in place in some European countries and other parts of the world. Clinicians should refer to the guidelines of their practice area to determine the appropriate algorithm and protocols to use. (See <a class="local">'Implementation'</a> above.)</p><p></p><p class="headingAnchor" id="H446271943"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Carolyn A Altman, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tennant PW, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet 2010; 375:649.</a></li><li><a class="nounderline abstract_t">Bird TM, Hobbs CA, Cleves MA, et al. National rates of birth defects among hospitalized newborns. Birth Defects Res A Clin Mol Teratol 2006; 76:762.</a></li><li><a class="nounderline abstract_t">Canfield MA, Honein MA, Yuskiv N, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 2006; 76:747.</a></li><li><a class="nounderline abstract_t">Oster ME, Lee KA, Honein MA, et al. Temporal trends in survival among infants with critical congenital heart defects. Pediatrics 2013; 131:e1502.</a></li><li><a class="nounderline abstract_t">Wren C, Reinhardt Z, Khawaja K. Twenty-year trends in diagnosis of life-threatening neonatal cardiovascular malformations. Arch Dis Child Fetal Neonatal Ed 2008; 93:F33.</a></li><li><a class="nounderline abstract_t">Gregory J, Emslie A, Wyllie J, Wren C. Examination for cardiac malformations at six weeks of age. Arch Dis Child Fetal Neonatal Ed 1999; 80:F46.</a></li><li><a class="nounderline abstract_t">Samánek M, Slavík Z, Zborilová B, et al. Prevalence, treatment, and outcome of heart disease in live-born children: a prospective analysis of 91,823 live-born children. Pediatr Cardiol 1989; 10:205.</a></li><li><a class="nounderline abstract_t">Peterson C, Ailes E, Riehle-Colarusso T, et al. Late detection of critical congenital heart disease among US infants: estimation of the potential impact of proposed universal screening using pulse oximetry. JAMA Pediatr 2014; 168:361.</a></li><li><a class="nounderline abstract_t">Kuehl KS, Loffredo CA, Ferencz C. Failure to diagnose congenital heart disease in infancy. Pediatrics 1999; 103:743.</a></li><li><a class="nounderline abstract_t">de-Wahl Granelli A, Wennergren M, Sandberg K, et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ 2009; 338:a3037.</a></li><li><a class="nounderline abstract_t">Eckersley L, Sadler L, Parry E, et al. Timing of diagnosis affects mortality in critical congenital heart disease. Arch Dis Child 2016; 101:516.</a></li><li><a class="nounderline abstract_t">Talner CN. Report of the New England Regional Infant Cardiac Program, by Donald C. Fyler, MD, Pediatrics, 1980;65(suppl):375-461. Pediatrics 1998; 102:258.</a></li><li><a class="nounderline abstract_t">Mahle WT, Newburger JW, Matherne GP, et al. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the AHA and AAP. Pediatrics 2009; 124:823.</a></li><li><a class="nounderline abstract_t">Oster ME, Aucott SW, Glidewell J, et al. Lessons Learned From Newborn Screening for Critical Congenital Heart Defects. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Lannering K, Kazamia K, Bergman G, et al. Screening for Critical Congenital Heart Defects in Sweden. Pediatrics 2023; 152.</a></li><li><a class="nounderline abstract_t">Khoshnood B, Lelong N, Houyel L, et al. Prevalence, timing of diagnosis and mortality of newborns with congenital heart defects: a population-based study. Heart 2012; 98:1667.</a></li><li><a class="nounderline abstract_t">Ailes EC, Gilboa SM, Honein MA, Oster ME. Estimated number of infants detected and missed by critical congenital heart defect screening. Pediatrics 2015; 135:1000.</a></li><li><a class="nounderline abstract_t">Lees MH. Cyanosis of the newborn infant. Recognition and clinical evaluation. J Pediatr 1970; 77:484.</a></li><li><a class="nounderline abstract_t">Schultz AH, Localio AR, Clark BJ, et al. Epidemiologic features of the presentation of critical congenital heart disease: implications for screening. Pediatrics 2008; 121:751.</a></li><li><a class="nounderline abstract_t">Chang RK, Gurvitz M, Rodriguez S. Missed diagnosis of critical congenital heart disease. Arch Pediatr Adolesc Med 2008; 162:969.</a></li><li><a class="nounderline abstract_t">Peterson C, Dawson A, Grosse SD, et al. Hospitalizations, costs, and mortality among infants with critical congenital heart disease: how important is timely detection? Birth Defects Res A Clin Mol Teratol 2013; 97:664.</a></li><li><a class="nounderline abstract_t">Zhao QM, Ma XJ, Ge XL, et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet 2014; 384:747.</a></li><li><a class="nounderline abstract_t">Garg LF, Van Naarden Braun K, Knapp MM, et al. Results from the New Jersey statewide critical congenital heart defects screening program. Pediatrics 2013; 132:e314.</a></li><li><a class="nounderline abstract_t">Abouk R, Grosse SD, Ailes EC, Oster ME. Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths. JAMA 2017; 318:2111.</a></li><li><a class="nounderline abstract_t">Sakai-Bizmark R, Kumamaru H, Marr EH, et al. Pulse Oximetry Screening: Association of State Mandates with Emergency Hospitalizations. Pediatr Cardiol 2023; 44:67.</a></li><li><a class="nounderline abstract_t">Ewer AK, Middleton LJ, Furmston AT, et al. Pulse oximetry screening for congenital heart defects in newborn infants (PulseOx): a test accuracy study. Lancet 2011; 378:785.</a></li><li><a class="nounderline abstract_t">Singh Y, Chen SE. Impact of pulse oximetry screening to detect congenital heart defects: 5 years' experience in a UK regional neonatal unit. Eur J Pediatr 2022; 181:813.</a></li><li><a class="nounderline abstract_t">Henderson A, Aguirre D, Singh A, Ewer AK. Temporal trends in routine predischarge pulse oximetry screening: 6 years' experience in a UK regional neonatal unit. Arch Dis Child Fetal Neonatal Ed 2022; 107:256.</a></li><li><a class="nounderline abstract_t">Plana MN, Zamora J, Suresh G, et al. Pulse oximetry screening for critical congenital heart defects. Cochrane Database Syst Rev 2018; 3:CD011912.</a></li><li><a class="nounderline abstract_t">Powell R, Pattison HM, Bhoyar A, et al. Pulse oximetry screening for congenital heart defects in newborn infants: an evaluation of acceptability to mothers. Arch Dis Child Fetal Neonatal Ed 2013; 98:F59.</a></li><li><a class="nounderline abstract_t">Mahle WT, Martin GR, Beekman RH 3rd, et al. Endorsement of Health and Human Services recommendation for pulse oximetry screening for critical congenital heart disease. Pediatrics 2012; 129:190.</a></li><li><a class="nounderline abstract_t">Kemper AR, Mahle WT, Martin GR, et al. Strategies for implementing screening for critical congenital heart disease. Pediatrics 2011; 128:e1259.</a></li><li><a class="nounderline abstract_t">Martin GR, Ewer AK, Gaviglio A, et al. Updated Strategies for Pulse Oximetry Screening for Critical Congenital Heart Disease. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Mouledoux J, Guerra S, Ballweg J, et al. A novel, more efficient, staged approach for critical congenital heart disease screening. J Perinatol 2017; 37:288.</a></li><li><a class="nounderline abstract_t">Diller CL, Kelleman MS, Kupke KG, et al. A Modified Algorithm for Critical Congenital Heart Disease Screening Using Pulse Oximetry. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Valmari P. Should pulse oximetry be used to screen for congenital heart disease? Arch Dis Child Fetal Neonatal Ed 2007; 92:F219.</a></li><li><a class="nounderline abstract_t">Richmond S, Reay G, Abu Harb M. Routine pulse oximetry in the asymptomatic newborn. Arch Dis Child Fetal Neonatal Ed 2002; 87:F83.</a></li><li><a class="nounderline abstract_t">Koppel RI, Druschel CM, Carter T, et al. Effectiveness of pulse oximetry screening for congenital heart disease in asymptomatic newborns. Pediatrics 2003; 111:451.</a></li><li><a class="nounderline abstract_t">Thangaratinam S, Daniels J, Ewer AK, et al. Accuracy of pulse oximetry in screening for congenital heart disease in asymptomatic newborns: a systematic review. Arch Dis Child Fetal Neonatal Ed 2007; 92:F176.</a></li><li><a class="nounderline abstract_t">Reich JD, Connolly B, Bradley G, et al. Reliability of a single pulse oximetry reading as a screening test for congenital heart disease in otherwise asymptomatic newborn infants: the importance of human factors. Pediatr Cardiol 2008; 29:371.</a></li><li><a class="nounderline abstract_t">Poets CF, Stebbens VA. Detection of movement artifact in recorded pulse oximeter saturation. Eur J Pediatr 1997; 156:808.</a></li><li><a class="nounderline abstract_t">Fouzas S, Priftis KN, Anthracopoulos MB. Pulse oximetry in pediatric practice. Pediatrics 2011; 128:740.</a></li><li><a class="nounderline abstract_t">Thangaratinam S, Brown K, Zamora J, et al. Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis. Lancet 2012; 379:2459.</a></li><li><a class="nounderline abstract_t">Kochilas LK, Menk JS, Saarinen A, et al. A comparison of retesting rates using alternative testing algorithms in the pilot implementation of critical congenital heart disease screening in Minnesota. Pediatr Cardiol 2015; 36:550.</a></li><li><a class="nounderline abstract_t">Hoke TR, Donohue PK, Bawa PK, et al. Oxygen saturation as a screening test for critical congenital heart disease: a preliminary study. Pediatr Cardiol 2002; 23:403.</a></li><li><a class="nounderline abstract_t">Oster ME, Colarusso T, Glidewell J. Screening for critical congenital heart disease: a matter of sensitivity. Pediatr Cardiol 2013; 34:203.</a></li><li><a class="nounderline abstract_t">Wright J, Kohn M, Niermeyer S, Rausch CM. Feasibility of critical congenital heart disease newborn screening at moderate altitude. Pediatrics 2014; 133:e561.</a></li><li><a class="nounderline abstract_t">Paranka MS, Brown JM, White RD, et al. The impact of altitude on screening for critical congenital heart disease. J Perinatol 2018; 38:530.</a></li><li><a class="nounderline abstract_t">Han LM, Klewer SE, Blank KM, et al. Feasibility of pulse oximetry screening for critical congenital heart disease at 2643-foot elevation. Pediatr Cardiol 2013; 34:1803.</a></li><li><a class="nounderline abstract_t">Samuel TY, Bromiker R, Mimouni FB, et al. Newborn oxygen saturation at mild altitude versus sea level: implications for neonatal screening for critical congenital heart disease. Acta Paediatr 2013; 102:379.</a></li><li><a class="nounderline abstract_t">Hoffman JI. Is Pulse Oximetry Useful for Screening Neonates for Critical Congenital Heart Disease at High Altitudes? Pediatr Cardiol 2016; 37:812.</a></li><li><a class="nounderline abstract_t">Lueth E, Russell L, Duster M, et al. A Novel Approach to Critical Congenital Heart Disease (CCHD) Screening at Moderate Altitude. Int J Neonatal Screen 2016; 2:4.</a></li><li><a class="nounderline abstract_t">Evers PD, Vernon MM, Schultz AH. Critical congenital heart disease screening practices among licensed midwives in washington state. J Midwifery Womens Health 2015; 60:206.</a></li><li><a class="nounderline abstract_t">Lhost JJ, Goetz EM, Belling JD, et al. Pulse oximetry screening for critical congenital heart disease in planned out-of-hospital births. J Pediatr 2014; 165:485.</a></li><li><a class="nounderline abstract_t">Cawsey MJ, Noble S, Cross-Sudworth F, Ewer AK. Feasibility of pulse oximetry screening for critical congenital heart defects in homebirths. Arch Dis Child Fetal Neonatal Ed 2016; 101:F349.</a></li><li><a class="nounderline abstract_t">Narayen IC, Blom NA, Bourgonje MS, et al. Pulse Oximetry Screening for Critical Congenital Heart Disease after Home Birth and Early Discharge. J Pediatr 2016; 170:188.</a></li><li><a class="nounderline abstract_t">Narayen IC, Blom NA, Verhart MS, et al. Adapted protocol for pulse oximetry screening for congenital heart defects in a country with homebirths. Eur J Pediatr 2015; 174:129.</a></li><li><a class="nounderline abstract_t">Miller KK, Vig KS, Goetz EM, et al. Pulse oximetry screening for critical congenital heart disease in planned out of hospital births and the incidence of critical congenital heart disease in the Plain community. J Perinatol 2016; 36:1088.</a></li><li><a class="nounderline abstract_t">Manja V, Mathew B, Carrion V, Lakshminrusimha S. Critical congenital heart disease screening by pulse oximetry in a neonatal intensive care unit. J Perinatol 2015; 35:67.</a></li><li><a class="nounderline abstract_t">Murphy D, Pak Y, Cleary JP. Pulse Oximetry Overestimates Oxyhemoglobin in Neonates with Critical Congenital Heart Disease. Neonatology 2016; 109:213.</a></li><li><a class="nounderline abstract_t">Van Naarden Braun K, Grazel R, Koppel R, et al. Evaluation of critical congenital heart defects screening using pulse oximetry in the neonatal intensive care unit. J Perinatol 2017; 37:1117.</a></li><li><a class="nounderline abstract_t">Goetz EM, Magnuson KM, Eickhoff JC, et al. Pulse oximetry screening for critical congenital heart disease in the neonatal intensive care unit. J Perinatol 2016; 36:52.</a></li><li><a class="nounderline abstract_t">Kochilas LK, Lohr JL, Bruhn E, et al. Implementation of critical congenital heart disease screening in Minnesota. Pediatrics 2013; 132:e587.</a></li><li><a class="nounderline abstract_t">Peterson C, Grosse SD, Oster ME, et al. Cost-effectiveness of routine screening for critical congenital heart disease in US newborns. Pediatrics 2013; 132:e595.</a></li><li><a class="nounderline abstract_t">Roberts TE, Barton PM, Auguste PE, et al. Pulse oximetry as a screening test for congenital heart defects in newborn infants: a cost-effectiveness analysis. Arch Dis Child 2012; 97:221.</a></li><li><a class="nounderline abstract_t">Grosse SD, Peterson C, Abouk R, et al. Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review. Int J Neonatal Screen 2017; 3:34.</a></li><li><a class="nounderline abstract_t">Reeder MR, Kim J, Nance A, et al. Evaluating cost and resource use associated with pulse oximetry screening for critical congenital heart disease: Empiric estimates and sources of variation. Birth Defects Res A Clin Mol Teratol 2015; 103:962.</a></li><li><a class="nounderline abstract_t">Glidewell J, Grosse SD, Riehle-Colarusso T, et al. Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018. MMWR Morb Mortal Wkly Rep 2019; 68:107.</a></li><li><a class="nounderline abstract_t">Manzoni P, Martin GR, Sanchez Luna M, et al. Pulse oximetry screening for critical congenital heart defects: a European consensus statement. Lancet Child Adolesc Health 2017; 1:88.</a></li><li><a class="nounderline abstract_t">Narayen IC, Blom NA, Ewer AK, et al. Aspects of pulse oximetry screening for critical congenital heart defects: when, how and why? Arch Dis Child Fetal Neonatal Ed 2016; 101:F162.</a></li><li><a class="nounderline abstract_t">de-Wahl Granelli A, Meberg A, Ojala T, et al. Nordic pulse oximetry screening--implementation status and proposal for uniform guidelines. Acta Paediatr 2014; 103:1136.</a></li><li><a class="nounderline abstract_t">Al Mazrouei SK, Moore J, Ahmed F, et al. Regional implementation of newborn screening for critical congenital heart disease screening in Abu Dhabi. Pediatr Cardiol 2013; 34:1299.</a></li><li><a class="nounderline abstract_t">Martin GR, Beekman RH 3rd, Mikula EB, et al. Implementing recommended screening for critical congenital heart disease. Pediatrics 2013; 132:e185.</a></li></ol></div><div id="topicVersionRevision">Topic 101291 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20092884" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 20-year survival of children born with congenital anomalies: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17063529" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : National rates of birth defects among hospitalized newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051527" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23610203" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Temporal trends in survival among infants with critical congenital heart defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556383" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Twenty-year trends in diagnosis of life-threatening neonatal cardiovascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325812" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Examination for cardiac malformations at six weeks of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2687820" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence, treatment, and outcome of heart disease in live-born children: a prospective analysis of 91,823 live-born children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24493342" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Late detection of critical congenital heart disease among US infants: estimation of the potential impact of proposed universal screening using pulse oximetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10103296" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Failure to diagnose congenital heart disease in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131383" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26130379" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Timing of diagnosis affects mortality in critical congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9651450" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Report of the New England Regional Infant Cardiac Program, by Donald C. Fyler, MD, Pediatrics, 1980;65(suppl):375-461.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581259" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the AHA and AAP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27244826" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lessons Learned From Newborn Screening for Critical Congenital Heart Defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37732389" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Screening for Critical Congenital Heart Defects in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22888161" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence, timing of diagnosis and mortality of newborns with congenital heart defects: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25963011" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Estimated number of infants detected and missed by critical congenital heart defect screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5502102" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cyanosis of the newborn infant. Recognition and clinical evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381540" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epidemiologic features of the presentation of critical congenital heart disease: implications for screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838650" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Missed diagnosis of critical congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24000201" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hospitalizations, costs, and mortality among infants with critical congenital heart disease: how important is timely detection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24768155" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23858425" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Results from the New Jersey statewide critical congenital heart defects screening program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29209720" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36273322" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pulse Oximetry Screening: Association of State Mandates with Emergency Hospitalizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21820732" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pulse oximetry screening for congenital heart defects in newborn infants (PulseOx): a test accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34618229" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of pulse oximetry screening to detect congenital heart defects: 5 years' experience in a UK regional neonatal unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34686534" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Temporal trends in routine predischarge pulse oximetry screening: 6 years' experience in a UK regional neonatal unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29494750" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pulse oximetry screening for critical congenital heart defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22611113" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulse oximetry screening for congenital heart defects in newborn infants: an evaluation of acceptability to mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22201143" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endorsement of Health and Human Services recommendation for pulse oximetry screening for critical congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987707" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Strategies for implementing screening for critical congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32499387" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Updated Strategies for Pulse Oximetry Screening for Critical Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27831548" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A novel, more efficient, staged approach for critical congenital heart disease screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29691284" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A Modified Algorithm for Critical Congenital Heart Disease Screening Using Pulse Oximetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449857" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Should pulse oximetry be used to screen for congenital heart disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193511" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Routine pulse oximetry in the asymptomatic newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612220" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effectiveness of pulse oximetry screening for congenital heart disease in asymptomatic newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17344253" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Accuracy of pulse oximetry in screening for congenital heart disease in asymptomatic newborns: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932712" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reliability of a single pulse oximetry reading as a screening test for congenital heart disease in otherwise asymptomatic newborn infants: the importance of human factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9365075" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Detection of movement artifact in recorded pulse oximeter saturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21930554" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pulse oximetry in pediatric practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22554860" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25304248" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A comparison of retesting rates using alternative testing algorithms in the pilot implementation of critical congenital heart disease screening in Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12170356" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oxygen saturation as a screening test for critical congenital heart disease: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23179425" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Screening for critical congenital heart disease: a matter of sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24567022" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Feasibility of critical congenital heart disease newborn screening at moderate altitude.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29379160" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The impact of altitude on screening for critical congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23677390" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Feasibility of pulse oximetry screening for critical congenital heart disease at 2643-foot elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23298328" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Newborn oxygen saturation at mild altitude versus sea level: implications for neonatal screening for critical congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27090652" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Is Pulse Oximetry Useful for Screening Neonates for Critical Congenital Heart Disease at High Altitudes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Novel Approach to Critical Congenital Heart Disease (CCHD) Screening at Moderate Altitude</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25782853" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Critical congenital heart disease screening practices among licensed midwives in washington state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24948344" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pulse oximetry screening for critical congenital heart disease in planned out-of-hospital births.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26915671" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Feasibility of pulse oximetry screening for critical congenital heart defects in homebirths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746119" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulse Oximetry Screening for Critical Congenital Heart Disease after Home Birth and Early Discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24990493" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Adapted protocol for pulse oximetry screening for congenital heart defects in a country with homebirths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27583398" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pulse oximetry screening for critical congenital heart disease in planned out of hospital births and the incidence of critical congenital heart disease in the Plain community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25058746" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Critical congenital heart disease screening by pulse oximetry in a neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26800085" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pulse Oximetry Overestimates Oxyhemoglobin in Neonates with Critical Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28749481" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Evaluation of critical congenital heart defects screening using pulse oximetry in the neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26540249" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pulse oximetry screening for critical congenital heart disease in the neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958775" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Implementation of critical congenital heart disease screening in Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23918890" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cost-effectiveness of routine screening for critical congenital heart disease in US newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247242" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pulse oximetry as a screening test for congenital heart defects in newborn infants: a cost-effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29376140" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26215888" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evaluating cost and resource use associated with pulse oximetry screening for critical congenital heart disease: Empiric estimates and sources of variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30730872" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169211" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pulse oximetry screening for critical congenital heart defects: a European consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369369" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Aspects of pulse oximetry screening for critical congenital heart defects: when, how and why?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25060211" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nordic pulse oximetry screening--implementation status and proposal for uniform guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532467" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Regional implementation of newborn screening for critical congenital heart disease screening in Abu Dhabi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23776113" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Implementing recommended screening for critical congenital heart disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
